Valuation : Genmab A/S

Market Cap 129B 20.09B 17.31B 16.23B 14.81B 27.91B 1,920B 27.99B 193B 75.12B 969B 75.41B 73.77B 3,213B P/E 2026 *
27.4x
P/E 2027 * 19.4x
Enterprise Value 149B 23.13B 19.93B 18.69B 17.06B 32.14B 2,211B 32.24B 222B 86.51B 1,116B 86.85B 84.96B 3,700B EV / Sales 2026 *
5.14x
EV / Sales 2027 * 4.17x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week+0.23%
Current month+16.01%
1 month+13.00%
3 months+26.86%
6 months+15.76%
Current year+6.36%
1 week 2,092
Extreme 2092
2,198
1 month 1,819.5
Extreme 1819.5
2,198
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+0.23%+33.71%-18.02% 20.17B
-1.59%-6.25%+64.99%+99.09% 70.64B
-1.34%-0.75%+48.56%+90.63% 66.11B
-8.19%-11.97%+0.68%-14.97% 27.98B
-2.40%-6.04%-12.45%+446.58% 26.51B
+0.30%+2.03%+59.48%+14.21% 26.44B
-0.96%+12.36%+280.38%+439.54% 20.4B
-1.91%-3.47%+11.03%+508.52% 15.99B
-1.81%+0.20%+42.98%+144.32% 13.69B
-4.01%-2.41%+280.55%+207.36% 12.51B
Average -2.28%+1.13%+80.99%+191.73% 30.04B
Weighted average by Cap. -2.09%+1.23%+65.70%+153.42%

Financials

2026 *2027 *
Net sales 29.01B 4.5B 3.88B 3.64B 3.32B 6.26B 430B 6.28B 43.17B 16.84B 217B 16.91B 16.54B 720B 33.71B 5.23B 4.51B 4.23B 3.86B 7.27B 500B 7.29B 50.16B 19.57B 252B 19.65B 19.22B 837B
Net income 4.93B 765M 659M 618M 564M 1.06B 73.12B 1.07B 7.33B 2.86B 36.91B 2.87B 2.81B 122B 7.13B 1.11B 954M 894M 816M 1.54B 106B 1.54B 10.61B 4.14B 53.4B 4.16B 4.07B 177B
Net Debt 19.62B 3.05B 2.62B 2.46B 2.25B 4.23B 291B 4.25B 29.2B 11.39B 147B 11.44B 11.19B 487B 11.13B 1.73B 1.49B 1.4B 1.27B 2.4B 165B 2.41B 16.56B 6.46B 83.36B 6.49B 6.35B 276B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-08-28 DKK 2,156.00 -0.51% 80,778
26-08-27 DKK 2,167.00 +0.37% 71,248
26-08-26 DKK 2,159.00 -1.68% 100,182
26-08-25 DKK 2,196.00 +3.98% 103,642
26-08-24 DKK 2,112.00 -1.81% 103,114
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,167.00DKK
Average target price
2,410.46DKK
Spread / Average Target
+11.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock